TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07746895: Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study

Sponsor: Swedish Orphan Biovitrum · Phase: PHASE4 · Area: IMMUNOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$331,200

Rescue Site Savings

+$220,800

Unlock Full NCT07746895 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07746895 Rescue Dossier →